Ticker
ACLX

Price
17.67
Stock movement down
-0.75 (-4.07%)
Company name
Arcellx Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
773.71M
Ent verdi
668.35M
Pris/omsetning
-
Pris/bok
3.49
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-
3 års avkastning
-
5 års avkastning
-
10 års avkastning
-
Sist oppdatert: 2022-08-25

UTBYTTE

ACLX betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning-
Pris til bok3.49
EV i forhold til salg-

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall43.79M
EPS (TTM)-3.17
FCF per aksje (TTM)-2.00

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)0.00
Bruttofortjeneste (TTM)0.00
Driftsinntekter (TTM)-62.23M
Netto inntekt (TTM)-106.45M
EPS (TTM)-3.17
EPS (1 år fremover)-4.15

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenestemargin (TTM)-

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter127.16M
Netto fordringer0.00
Samlede omløpsmidler220.90M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler243.39M
Leverandørgjeld1.87M
Kortsiktig/nåværende langsiktig gjeld5.21M
Sum kortsiktig gjeld16.81M
Sum gjeld21.80M
Aksjonærenes egenkapital221.59M
Netto varige driftsmidler221.59M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-61.41M
Kapitalutgifter (TTM)5.83M
Fri kontantstrøm (TTM)-67.24M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-48.04%
Avkastning på eiendeler-43.74%
Avkastning på investert kapital-47.96%
Kontantavkastning på investert kapital-30.29%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning18.58
Daglig høy18.58
Daglig lav17.44
Daglig volum138K
Tidenes høyeste24.43
1 år analytikerestimat29.50
Beta-
EPS (TTM)-3.17
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon-

Nedsidepotensial

Loading...
Nedsidepotensial-data
ACLXS&P500
Nåværende prisfall fra toppnotering-27.67%-12.18%
Høyeste prisfall-62.33%-56.47%
Dato for høyeste fall18 May 20229 Mar 2009
Gj.snittlig fall fra topp-25.22%-11.38%
Gj.snittlig tid til ny topp18 days12 days
Maks tid til ny topp70 days1805 days
SELSKAPSOPPLYSNINGER
ACLX (Arcellx Inc) company logo
Markedsverdi
773.71M
Markedsverdi kategori
Small-cap
Beskrivelse
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Ansatte
78
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
USA
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
The mean of analysts' price targets for Arcellx, Inc. (ACLX) points to a 61.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an...
8. september 2022
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today report...
15. august 2022
Gaithersburg's Arcellx Inc. (NASDAQ: ACLX) has inked a deal to expand into Rockville. The newly minted public company, a clinical-stage provider of cell therapies for cancer and autoimmune diseases, ...
1. august 2022
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
23. juni 2022
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announ...
21. juni 2022
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announ...
21. juni 2022
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announ...
16. juni 2022
The American Society of Clinical Oncology (ASCO) just finished up its annual meeting. We have some winners coming out of the conference.
10. juni 2022
Newcomer Arcellx could rival Johnson & Johnson in multiple myeloma, an analyst said as the biotech popped to a two-month high.
6. juni 2022
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announ...
3. juni 2022
Neste side